Sanofi to accelerate mRNA vaccines through new Center of Excellence
The company will invest €400 million per year to advance mRNA technology beyond the pandemic
Sanofi plans to create a Center of Excellence to advance vaccines using mRNA technology across sites at Cambridge, Massachusetts and Marcy l'Etoile in France, the French pharmaceutical company has announced.
Approximately 400 employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and CMC (chemistry, manufacturing and controls) teams across the two sites will work to develop mRNA vaccines across all infectious disease areas.
To fund the Center of Excellence, the French company has pledged a "massive" investment — approximately €400 million a year.
The Center will work to accelerate the mRNA vaccines portfolio developed through the collaboration it established with specialist mRNA therapeutics company Translate Bio in 2018 and expanded in 2020.
Under the agreement, the companies are jointly conducting research and development activities to advance mRNA vaccines and mRNA vaccine platform development during a research term of at least four years after the original signing in 2018.
During the COVID-19 pandemic, mRNA technology stole a march on alternatives and demonstrated its potential to deliver new vaccines quickly. Now, Sanofi is keen to innovate mRNA vaccines beyond the pandemic to routine use in diseases with high unmet need.
Thomas Triomphe, Executive Vice President, Global Head of Sanofi's vaccine unit, Sanofi Pasteur said: “Although mRNA won’t be the solution for every infectious disease ... It now becomes a critical new technology in our comprehensive vaccines toolbox, one which could help reinvent health protection in the future.”
Sanofi says it expects to develop a minimum of six clinical candidates by 2025.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance